

Provincial Frozen Plasma (FP)/Prothrombin Complex Concentrate (PCC) Utilization Audit



Table of Contents

FP/PCC Audit Protocol	3
FP/PCC Audit- Manual Data Entry Form	5
FP/PCC Audit Question Instruction Sheet	10
FP/PCC Audit Tool Quick Guide	14
FP/PCC Audit Patient Tracking Log (Form 1)	17

You will find all the information needed to conduct your audit within this package. If you require additional information or have any questions, please contact:

Troy Thompson, Regional Project Coordinator Ontario Regional Blood Coordinating Network, Central region Telephone: 416.480.6100 Ext. 89435

Cell: 289-339-6648

Email: troy.thompson@sunnybrook.ca

On behalf of,

Ontario Regional Blood Coordinating Network



Provincial Frozen Plasma (FP)/Prothrombin Complex Concentrate (PCC) Utilization Audit – 2013

Purpose and Rationale

The goal of the FP/PCC utilization audit is to determine whether the introduction of the Ontario Recommendations for the Use of FP and the implementation of PCC have resulted in a reduction in the inappropriate use of FP. An initial baseline FP audit conducted in 2008, found that 54.8% of orders for frozen plasma were "appropriate", 28.6% "inappropriate" and 16.6% "indeterminate". A web-based audit tool has been created to for to audit the utilization of these blood products.

Following the provincial plasma audit in 2008, Ontario recommendations for the use of FP were developed and disseminated to all Ontario hospitals to provide guidance for the appropriate use of frozen plasma. Guidelines for the use of PCC were published by the National Blood Advisory Committee on Blood and Blood Products (NAC) and disseminated to Ontario hospitals in 2009.

At the time of the first provincial FP audit, PCC were being introduced into Ontario hospitals to be used for the urgent reversal of warfarin, therefore the initial audit did not capture PCC utilization data. The Plasma Audit Steering Committee has recommended that the use of PCC be captured in this subsequent provincial audit.

Population to be studied

This data collection project will focus on all patients being transfused with FP or PCC. There will be no interaction with patients to collect this data; the data elements required are listed below:

- Hospital site (coded)
- Patient care area
- Date of transfusion
- Patient identification by study code number
- Patient age (YOB)
- Gender
- Indication for FP/PCC transfusion including baseline coagulation results
- Number of units/vials ordered and transfused
- Ordering physician specialty

Each order will be assigned an order number for entry into a secure database. Other than the patient's year of birth and gender, there is no patient specific data that will be entered



in the electronic audit tool. The database is housed on a SQL secure server housed by the Ontario Regional Blood Coordinating Network portal.

Provincial FP/PCC Audit Methods

A prospective review of the clinical indications and laboratory data in all transfusion episodes of FP and PCC occurring in all participating Ontario hospitals will take place for any five days chosen by the site between Monday November 18th and Friday December 13th. The 5 day period does not need to be consecutive days. For the participating sites that utilize plasma or PCCs infrequently, please choose the days in which you receive orders for plasma or PCC to audit. (if possible).

Manual data entry forms have been included in this audit package for those sites that would find it easier to log the order data manually and subsequently enter the information into the electronic audit tool.

In addition, a **FP/PCC Audit Patient Tracking Log** is included for sites to log patient specific information. This information will not be entered into the electronic tool and can be used internally at each site. The purpose of the log is to maintain the patients' anonymity and allow for cross-referencing should there be a reason to investigate data discrepancies. The electronic audit tool will automatically assign an order number. Please record the order number on the FP/PCC Audit Patient Tracking Log.

At the conclusion of the provincial audit, a review of the utilization data will be used to determine whether or not ordering practices have improved since the baseline audit was conducted in 2008. This data will be used to determine future strategies to influence ordering and infusion practices of FP and PCC.

FP/PCC Audit- Manual Data Entry Form

Facility details (only needs to be completed once per facility)

1. a) Does your facility have institutional guidelines for the use of Frozen Plasma? $\ \Box$ Yes $\ \Box$ No
b) If yes, are the guidelines in line with the Ontario Recommendations for the Use of Frozen Plasma that were released in 2008? \square Yes \square No Link to Ontario Recommendations
2. Does your facility stock prothrombin complex concentrate (PCC)? \Box Yes \Box No
3. Does your facility have guidelines for the use of PCC? \square Yes \square No

FP/PCC Audit- Manual Data Entry Form

FP/PCC Transfusion Order

1. Patient age: years/months
2. Transfusion date:
3. Patient sex: □ M □ F
4. a) Is the patient on anticoagulants? \square Yes \square No \square Don't know
b) If yes, which one (check all that apply) Heparin Low molecular weight heparin Fondoparinux (Arixta) Dabigatran (Pradaxa) Apixaban (Eliquis) Warfarin (Coumadin) Rivaroxaban (Xarelto) Don't know Other (please specify)
5. a) Does the patient have a coagulopathy ? □ Yes □ No □ Don't know
b) Is yes, which one? DIC Vitamin K deficiency Liver disease Sepsis Massive transfusion Clotting factor deficiency Trauma Unknown
6. Bleeding status: \square No Bleeding \square Minor Bleeding \square Major Bleeding \square Unknown
Major bleeding: defined as hemorrhage sufficient to require at least one RBC within 24 hours OR intracranial OR spinal bleeding OR hemoglobin drop to <80 g/L Minor bleeding: defined as all other bleeding situations not meeting definition of major bleeding as above.

7. Specialty of o	ordering physic	ian:				
□ Anesthesia	☐ Cardiology		☐ Critical care:	□ Cri medi	tical care:	☐ Dermatology
☐ Emergency	☐ Gastroenter	ology	☐ General Practice/Family	□ Не	matology	☐ Immunology
			Medicine			
☐ Infectious Disease	□ Internal Me	dicine	□ Neonatology	□Ne	phrology	☐ Neurology
☐ Obstetrics and Gynecology	□ Oncology		☐ Pediatric- General	□ Ra	diology	☐ Respirology
☐ Rheumatology	☐ Surgery:	_	☐ Surgery:		rgery:	☐ Surgery:
	Cardiovascula	r	General	Neuro	osurgery	Orthopedic
☐ Surgery: Other	□ Unknown		□ Other			
			(please specify)			
0 3 44 .1	1 / .			7 N.T		
8. a) Was there	a procedure/of	ther in	dication? □ Yes □	l No		
b) If there was a	a procedure, se	lect fro	m the list below:			
☐ Central line	□ Exchange		Fine needle		age guided	☐ Kidney biopsy
placement	transfusion	as	pirate	thera	py	
☐ Liver Biopsy	☐ Paracentesis		Plasma exchange	□ Sui	rgery	☐ Thoracentesis
			nerapeutic heresis)			
□ Unknown	□ Other					
□ Olikilowii	(please specify)					
c) If there was a procedure, was the procedure to be performed within 6 hours of						
administration of the blood component? ☐ Yes ☐ No ☐ Unknown						
9. If there was another indication, select from the list below:						
☐ DIC (Disseminated intravascular coagulation) ☐ Vitamin		amin K deficiency		☐ Liver Dise	ease	
		□Ма	ssive transfusion		Clotting f	actor deficiency
-					☐ Clotting factor deficiency	
□ Trauma	□ Unl		nknown		\square No other indication	

□ Other (please specify)_____

Product ordered/transfused				
10. Product ordered: FP unit(s) PCCvial(s)				
11. Product transfused: FPunit(s) Apheresis 250 mLunit(s) Apheresis 500 mLunit(s) Cryosupernatant plasmaunit(s) PCCvial(s)				
12. Issued to locati	on:			
☐ Apheresis	☐ Coronary care unit	☐ Diagnostic imaging	☐ Dialysis	
☐ Emergency room	☐ Endoscopy	□ICU	☐ ICU:Cardiovascular	
☐ ICU:Neonatal	☐ Medical ward	☐ Operating room	☐ Outpatient clinic	
□ Recovery room	□ Surgical ward	□ Unknown	☐ Other- (please specify)	
Pre-transfusion blood work: 13. a) Was a pre-transfusion INR ordered (within 24 hours)? □ Yes □ Yes-results pending □No				
b) If yes, what was		□1617		
□ 0-1.2 □ 2.0-3.0	□ 1.3-1.5	☐ 1.6-1.7 ☐ 5.1-10.0	☐ 1.8-1.9 ☐ >10.0	
14. a) Was a pre-transfusion aPTT ordered (within 24 hours)? ☐ Yes ☐ Yes-results pending ☐ No b) If yes, what was the aPTT result?				
☐ Within normal range	□ between upper line of normal range and 1.5 X upper limit of normal range	d of normal range	imit □ >2.0 X upper limit of normal range	

Post-transfusion blood work:					
15. a) Was a post-transfusion INR ordered (within 6 hours)?					
\square Yes \square Yes-results pending \square No					
b) If yes, what was the	INR res	ult?			
□ 0-1.2	□ 1.3-1	5	□ 1.6-1.7		□ 1.8-1.9
□ 2.0-3.0	□ 3.1-5	5.0	□ 5.1-10.0		□ >10.0
16. a) Was a post-trans	fusion a	PTT ordered (v	within 6 hours)?		
☐ Yes ☐ Yes-results pe	nding [□No			
b) If yes, what was the aPTT result?					
\square Within normal		een upper	☐ 1.6-2.0 X upper limit		\square >2.0 X upper limit of
range	limit of normal range		of normal range		normal range
	and 1.5 X upper limit				
	of norm	nal range			
17. a) Was an adverse transfusion reaction (ATR) reported within 6 hours? \square Yes \square No b) If yes, what were the symptoms?					
☐ Chills		☐ Fever	□ Нуро		otension
☐ Dyspnea		☐ Hives, urtica	ria	☐ Tach	ycardia
□ Other (please specify)					
c) If yes, what was the ATR diagnosis?					
☐ Acute hemolytic react	ion	☐ Allergic reac			ile non-hemolytic
\square TACO (Transfusion		\square TRALI (Tran			r (please
associated circulatory		acute lung inju	ry)	specify)
overload)					

Audit Question Instruction Sheet

Facility Details (facility questions will only need to be entered once into the audit		
tool)		
1. a) Does your facility have	Answer Yes or No.	
institutional guidelines for the use of	If yes, proceed to question 1. b)	
Frozen Plasma?	If no, proceed to question 2.	
1. b) If yes, are the guidelines in line	Answer Yes or No. ORBCoN released	
with the Ontario recommendations for	recommendations for the use of frozen	
the Use of Frozen Plasma that were	plasma in 2008. <u>View Ontario</u>	
released in 2008?	<u>Recommendations</u>	
	Proceed to question 2.	
2. Does your facility stock prothombin	Answer Yes or No. Prothrombin complex	
complex concentrate (PCC)?	concentrates include Octaplex and/or	
	Beriplex.	
3. Does your facility have guidelines for	Answer Yes or No. These could be the NAC	
the use of PCC?	guidelines or guidelines developed by your	
	facility.	

Plasma/Prothrombin Complex Concentr	ate Order
1. Patient age	Enter the patient's age in years or months (if
	patient a neonate).
2. Order date	Enter the date of the transfusion order.
3. Patient sex	Select either Male (M) or Female (F).
4. a) Is the patient on anticoagulants?	Select Yes or No or Unknown.
	If yes, proceed to question 4. b)
	If no, proceed to question 5.
	If unknown, proceed to question 5.
4. b) Is yes, which one?	Choose all anticoagulants that apply. Proceed
	to question 5. a).
5. a) Does the patient have a	Select Yes or No.
coagulopathy?	If yes, proceed to question 5. b)
	If no, proceed to question 6.
5. b) If yes, which coagulopathy does	Choose the coagulopathy the patient has. If
the patient have?	this information is not known, select
	Unknown. Proceed to question 6. Note:
	Massive transfusion will appear down below
	as an indication. If there is a known
	coagulopathy related to the massive
	transfusion, choose Yes here
6. Bleeding status	Select either No Bleeding , Minor bleeding ,
	Major bleeding or Unknown . Definition of
	minor and major bleeding on Manual form.
7. Specialty of ordering physician	Select the specialty of the ordering physician.
	Select "other" if specialty is not in list and

	record the specialty.
8. a) Was there a procedure/other indication?	Select Yes if the patient was going for a procedure or if there was another indication for the product. Proceed to 8 b). Select No if there wasn't a procedure or other indication. Proceed to question 9. Note: Massive transfusion also appears in the list of "other indications". It can be selected again as the indication, either with or without a coagulopathy.
b) If there was a procedure, which one?	Select the procedure. Proceed to 8. c)
c) If there was a procedure, was the procedure to be performed within 6	Select Yes, No or Unknown. Proceed to question 9. This question is included because
hours of administration of the blood component?	the use of PCC is recommended for "urgent" (within 6 hours) reversal of warfarin, plasma
component:	should not be used for urgent reversal.
9. If there was another indication which	Select the indication. Proceed to question 10.
one?	

Product ordered/transfused	
10. Product ordered	Select the number of units of FP ordered or
	the number of vials of PCCs ordered. Note:
	the assumption here is that each unit of
	plasma ordered is equivalent to a 250ml bag
11. Product transfused	Select the number of units of FP transfused or
	the number of vials of PCCs transfused.
	*Solvent detergent plasma should be entered as FP.
	Note: The audit tool will automatically count
	500ml apheresis units as "2" units of FP in the transfused data in the site report.
12. Issued to location	Select the location that the product(s) were
12. Issued to location	issued to. If location is not listed, select
	"other" and specify the location.
Pre-transfusion blood work	other and speeny the location.
13. a) Was a pre-transfusion INR	Select Yes if an INR was ordered within 6
ordered (within 24 hours)?	hours of the product order and if the results of
	the INR were available at the time of the
	product order. Proceed to question 13.b)
	Select Yes-results pending if an INR was
	ordered within 6 hours of the product order
	but the INR results were pending at time of
	product order. Proceed to question 14 a).
	Select No if an INR was not ordered within 6
	hours of the product order. Proceed to
	question 14 a).

12 h) If you what was the IND was 12	If an INR was ordered within 6 hours of the
13. b) If yes, what was the INR result?	
	product order and the results were available
	at time of order, select the range of the INR
	result.
	0-1.2
	1.3-1.5
	1.6-1.7
	1.8-1.9
	2.0-3.0
	3.1-5.0
	5.1-10.0
	>10.0
14. a) Was a pre-transfusion aPTT	Select Yes if an aPTT was ordered within 24
ordered (within 24 hours)?	hours of the product order and if the results of
	the aPTT were available at the time of the
	product order. Proceed to question 14.b)
	Select Yes-results pending if an aPTT was
	ordered within 24 hours of the product order
	but the aPTT results were pending at time of
	product order. Proceed to question 15. a)
	Select No if an aPTT was not ordered within
	24 hours of the product order. Proceed to
	question 15. a).
14. b) If yes, what was the aPTT result?	If an aPTT was ordered within 24 hours of the
	product order and the results were available
	at time of product order select the range of
	the aPTT result.
	-within normal range
	-1-1.5 X normal range
	-1-1.5 X normal range -1.6-2.0 X normal range
	-1-1.5 X normal range
Post-transfusion blood work	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6
	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b)
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 .
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 . Select No if an INR was not ordered within 6
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 . Select No if an INR was not ordered within 6 hours post-transfusion. Proceed to question
15. a) Was a post-transfusion INR ordered (within 6 hours)?	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 . Select No if an INR was not ordered within 6 hours post-transfusion. Proceed to question 16 .
15. a) Was a post-transfusion INR	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 . Select No if an INR was not ordered within 6 hours post-transfusion. Proceed to question 16 . If an INR was ordered within 6 hours post-
15. a) Was a post-transfusion INR ordered (within 6 hours)?	-1-1.5 X normal range -1.6-2.0 X normal range ->2.0 X normal range Select Yes if an INR was ordered within 6 hours post-transfusion. Proceed to question 15. b) Select Yes-results pending if an aPTT was ordered within 24 hours of the product order but the aPTT results were pending at time of product order. Proceed to question 16 . Select No if an INR was not ordered within 6 hours post-transfusion. Proceed to question 16 .

	1.3-1.5
	1.6-1.7
	1.8-1.9
	2.0-3.0
	3.1-5.0
	5.1-10.0
	>10.0
16. a) Was a post-transfusion aPTT	Select Yes if an aPTT was ordered within 6
ordered (within 6 hours)?	hours post-transfusion. Proceed to 16. b)
	Select Yes-results pending if an aPTT was
	ordered within 24 hours of the product order
	but the aPTT results were pending at time of
	product order. Proceed to question 17. a)
	Select No if an aPTT was not order within 6
	hours post-transfusion. Proceed to question
	17.a)
16. b) If yes, what was the aPTT result?	If an aPTT was ordered within 6 hours post-
	transfusion select the range of the aPTT
	result.
	within normal range
	1-1.5 X normal range
	1.6-2.0 X normal range
	>2.0 X normal range
17. a) Was an adverse transfusion	Select Yes if an adverse transfusion reaction
reaction (ATR) reported within 6	was reported within 6 hours post-transfusion.
hours?	Proceed to question 17. b)
	Select No if there was not an adverse
	transfusion reaction reported within 6 hours
	post-transfusion. You have completed the
	data entry for this order. Click Save to save
	this order.
17. b) If yes, what were the symptoms?	Select all the symptoms that apply to the
	adverse transfusion reaction. Proceed to
	question 17. c)
17. c) If yes, what was the adverse	Select the diagnosis for the adverse
transfusion reaction (ATR) diagnosis?	transfusion reaction. You have completed
	the data entry for this order. Click Save to
	save this order.


FP/PCC Audit Tool Quick Guide for Site Administrator

http://orbcon.transfusionontario.org/etools/index.php?c=security&m=login



Login

Enter Email address and Password and click Login. (this information will be provided to each hospital's site administrator)




Accessing Bloody Easy Audits application

Click anywhere on the Bloody Easy Audits box to open the audit programs.




Accessing Frozen Plasma Audit tool

Click on the Frozen Plasma Audit box to open the FP Audit Tool.




Entering audit data

Click on Add Order to enter the FP/PCC audit data for each order.




Facility Details

Enter the answers to the facility questions. (These questions only need to be answered once and will not appear again)




Subsequent audit data entry

Enter remaining audit data into application. (Instructions for audit questions can be found on Pg. 10)



Save audit data


Upon data entry for each order click on the Save button to save audit data.



Editing existing audit data for specific order

Click on Green "pencil" button to edit audit data on a specific order.

Report Manager Function



Form 1: FP/PCC Audit Patient Tracking Log

Order Number*	Order Date	Last Name	First Name	Hospital Identification Number	Data Entry Complete☑	Initials